证券代码：688329 证券简称：艾隆科技 公告编号：2025-040 苏州艾隆科技股份有限公司 股东及董监高减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 大股东及其一致行动人、董监高上市以来未减持股份。 重要内容提示： 大股东及董监高持有的基本情况 截至本公告披露日，苏州艾隆科技股份有限公司（以下简称"公司"）控股股 东、实际控制人张银花女士持有公司股份 23,055,000 股，占公司总股本的 29.86%， 上述股份为公司首次公开发行前取得的股份，已于 2025 年 4 月 1 日解除限售并 上市流通；董事长兼总经理徐立先生持有公司股份 8,458,000 股，占公司总股本 的 10.96%，其中 8,457,500 股为公司首次公开发行前取得的股份，已于 2024 年 4 月 10 日解除限售并上市流通，500 股通过集中竞价交易方式取得。 减持计划的主要内容 公司近日收到公司控股股东、实际控制人张银花女士以及公司董事长兼总经 理徐立先生出具的《减持股份计划告知函》。因自身资金需求， ...

格隆汇8月24日丨艾隆科技(688329.SH)公布，公司近日收到公司控股股东、实际控制人张银花女士以及 公司董事长兼总经理徐立先生出具的《减持股份计划告知函》。因自身资金需求，张银花女士拟通过集 中竞价或大宗交易方式减持所持有公司股份合计不超过100万股，占公司总股本的1.30%；徐立先生拟 通过集中竞价或大宗交易方式减持所持有公司股份合计不超过30万股，占公司总股本的0.39%。其中， 在任意连续90日内，拟通过集中竞价交易方式减持股份的总数不超过公司股份总数的1%；在任意连续 90日内，拟通过大宗交易减持股份的总数不超过公司股份总数的2%。 ...

Group 1 - The controlling shareholder and actual controller of Elon Technology, Zhang Yinhua, plans to reduce his holdings by up to 1 million shares, accounting for 1.30% of the total share capital, between September 16, 2025, and December 15, 2025 [1] - The reduction will occur through centralized bidding or block trading, with a maximum of 772,000 shares to be sold via centralized bidding [1] - Chairman and General Manager Xu Li also intends to reduce his holdings by up to 300,000 shares, representing 0.39% of the total share capital during the same period [1]

Core Viewpoint - The stock of Elon Technology (688329) has shown a slight increase in price, but the financial performance indicates challenges, particularly in revenue and net profit margins [1][3]. Financial Performance - As of the mid-2025 report, Elon Technology reported a main revenue of 131 million yuan, a year-on-year decrease of 8.11% [3]. - The net profit attributable to shareholders was -8.39 million yuan, which represents a year-on-year increase of 55.47% [3]. - The second quarter of 2025 saw a single-quarter main revenue of 75.01 million yuan, down 13.61% year-on-year [3]. - The company reported a gross margin of 40.69%, which is significantly higher than the industry average of 27.19% [3]. Market Position - Elon Technology's total market capitalization is 1.739 billion yuan, which is below the industry average of 7.683 billion yuan [3]. - The company ranks 256th in the industry based on total market value and 205th based on net assets [3]. - The price-to-earnings ratio is -103.65, indicating negative earnings, while the price-to-book ratio stands at 2.28, which is better than the industry average of 5.58 [3]. Capital Flow Analysis - On August 20, 2025, the stock experienced a net outflow of 755,000 yuan from main funds, accounting for 3.34% of the total transaction volume [1][2]. - Retail investors showed a net inflow of 2.1817 million yuan, representing 9.66% of the total transaction volume on the same day [1][2]. - Over the past five days, the stock has seen fluctuating capital flows, with significant outflows from main and speculative funds [2].

Group 1 - The SPD concept is gaining traction in the secondary market, with companies like Seli Medical, Guoke Hengtai, and Chongyao Holdings seeing significant stock price increases [1] - SPD stands for Supply, Processing, and Distribution, representing a modern supply chain management model in healthcare [1] - SPD business involves operators signing contracts with medical institutions to centralize the supply, inventory, processing, and distribution of medical materials [1] Group 2 - The SPD model allows companies to build smart supply chain management platforms for medical institutions, providing diversified services to enhance operational efficiency [1] - The introduction of lean management in SPD can reduce waste, optimize processes, and lower procurement costs for medical institutions [1] - The analyst predicts a substantial market demand for SPD in Chinese hospitals due to the rising costs of medical supplies, which account for 50% to 55% of hospital expenses [2] Group 3 - Companies are actively responding to the growing interest in SPD and hospital information technology on investor platforms [2] - Seli Medical claims a significant market share in SPD projects and aims to expand through regional cooperation [2] - Chongyao Holdings has implemented around 80 SPD projects across 14 provinces, serving nearly 70 medical institutions [2]

Group 1 - The stock of Elon Technology (688329) closed at 22.88 yuan on August 11, 2025, with an increase of 4.05% and a turnover rate of 2.99% [1] - The net inflow of retail funds was 248.23 million yuan, while the net outflow of main funds was 92.7 million yuan, indicating mixed investor sentiment [1] - The company reported a total market value of 1.766 billion yuan, which is significantly lower than the industry average of 7.347 billion yuan [4] Group 2 - Elon Technology's main revenue for the first half of 2025 was 131 million yuan, a year-on-year decrease of 8.11%, while the net profit attributable to shareholders was -8.39 million yuan, an increase of 55.47% year-on-year [4] - The company's gross profit margin stood at 40.69%, which is higher than the industry average of 27.41% [4] - The company specializes in intelligent management of medical supplies, providing comprehensive solutions for medical service institutions [4]

Core Viewpoint - Suzhou Ailong Technology Co., Ltd. plans to acquire a factory building from its affiliate, Chuzhou Zhuyi Technology Co., Ltd., for approximately RMB 13.5 million, which is part of a related party transaction [1][2][9]. Summary by Sections 1. Overview of Related Party Transaction - The transaction involves the purchase of a factory located at No. 1, Quanzhou Road, Chuzhou City, Anhui Province, by the company's subsidiary, Yigu Research Institute, for business development needs [2][6]. - The expected transaction price is RMB 13.5 million, funded by the subsidiary's own or self-raised funds [2][6]. 2. Board Approval Process - The transaction has been approved by the company's board and supervisory committee, with related directors abstaining from voting [3][10]. - The transaction does not require shareholder meeting approval as it does not meet the threshold [3][10]. 3. Transaction Counterparty Information - The seller, Chuzhou Zhuyi Technology Co., Ltd., was established on December 22, 2021, with a registered capital of RMB 150 million [4][5]. - The company is involved in real estate development and various management services [4][5]. 4. Asset Details - The factory building has a total area of 8,010.72 square meters and is not subject to any mortgages or legal disputes [6][8]. - The transaction price is based on market rates for similar properties and is deemed fair and reasonable [6][9]. 5. Impact on the Company - The transaction aligns with the company's long-term strategic goals and will not adversely affect its financial status or operational independence [9][10]. - The board and supervisory committee believe the transaction will benefit the subsidiary's sustainable development [10]. 6. Historical Related Transactions - The company previously announced a financing guarantee for Chuzhou Zhuyi Technology, which was approved by shareholders, but no actual guarantees have been provided to date [1][11].

证券代码：688329 证券简称：艾隆科技 公告编号：2025-036 苏州艾隆科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为积极响应上海证券交易所《关于开展沪市公司"提质增效重回报"专项行动 的倡议》，深入贯彻党的二十大和中央金融工作会议精神，落实国务院《关于进 一步提高上市公司质量的意见》要求，推动公司高质量发展和投资价值提升，保 护投资者尤其是中小投资者合法权益，助力资本市场健康发展，苏州艾隆科技股 份有限公司（以下简称"公司"）于 2025 年 5 月 21 日披露了 2025 年度"提质增效 重回报"专项行动方案。2025 年上半年，公司根据行动方案内容，积极开展和落 实各项工作，现将 2025 年上半年主要进展及成效情况报告如下： 一、聚焦主营业务，提升经营质量 但实现归属于母公司所有者的净利润-839.02 万元，较上年同期上升 55.47%。与 此同时，公司进一步落实预算管理工作，做好成本优化和费用管控，2025 年上 半年，公司主营业务成本 6,656.78 万元，同比下降 5.68 ...

| 证券简称：艾隆科技 公告编号：2025-038 | 证券代码：688329 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 苏州艾隆科技股份有限公司 | | | | | | | | 年半年度计提及转回资产减值准备的公告 | 2025 关于 | | | | | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 | | | | | | | | 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | | | | | | | | 一、本次计提减值准备情况概述 | | | | | | | | 根据《企业会计准则》以及公司会计政策、会计估计的相关规定，为了真实、 | | | | | | | | 2025 6 30 年 月 日的财务状况，本着谨慎性原则，对截至 | 准确地反映公司截至 | | | | | | | 值 准 备 。 2025 年 半 年 度 公 司 转 各 类 信 用 及 产 减 值 准 | 应 的 减 | 回 | 资 | 备 | 共 | 计 | | 单位：元 | | | | | | | | 202 ...

Company Overview - Suzhou Ailong Technology Co., Ltd. focuses on intelligent management of medical supplies, providing comprehensive solutions for healthcare institutions globally [4][10] - The company has established a complete product line covering smart pharmacies, smart wards, smart warehousing, and pharmaceutical information systems [4][10] - As of the reporting period, Ailong's products have been implemented in over 1,200 healthcare institutions, including more than 580 top-tier hospitals in China [4] Financial Performance - For the first half of 2025, the company reported a net profit attributable to shareholders of -8.39 million yuan, a year-on-year improvement of 55.47% [1][2] - Total revenue for the same period was approximately 131.08 million yuan, reflecting an 8.11% decrease compared to the previous year [2] - The total profit for the period was -7.55 million yuan, showing a significant improvement of 62.56% from -20.16 million yuan in the same period last year [2][3] Business Model - The company employs a mixed sales model combining direct sales and distribution through agents [8] - Direct sales target pharmaceutical supply chain service companies, healthcare institutions, and government entities, primarily through tendering processes [8] - The OEM procurement model allows the company to focus on core technology development while outsourcing some production to partners [7][8] Industry Context - The medical supply intelligent management system industry in China has evolved from initial automation attempts in the 1990s to comprehensive, integrated solutions in recent years [10] - Regulatory changes and the increasing complexity of healthcare demands have driven the shift towards "whole-hospital, integrated" solutions [10] - The industry is characterized by a growing need for automation and information integration to enhance efficiency and safety in medical supply management [10] Product Development - Ailong Technology emphasizes continuous innovation and product development, integrating automation and information technology to enhance operational efficiency [4][5] - The company has developed various products, including intelligent dispensing systems, automated drug storage, and management software for narcotic drugs [5][6] - Recent innovations include the "Ailong AI Assistant," which leverages AI to optimize various aspects of pharmaceutical management [7]